Source link : https://london-news.net/revolutionizing-hiv-prevention-new-injectable-prep-trial-for-women-launches-in-england/
A new clinical trial is introducing a biannual injection designed to lower the risk of HIV transmission for sexually active women in select regions of England.
This research will be conducted across France and the UK, with locations in Birmingham, Manchester, London, and Brighton.
Participants in the trial will receive a novel injectable form of PrEP (pre-exposure prophylaxis) named Lenacapivir, administered twice a year.
While PrEP is currently available on the NHS as a daily oral tablet—which substantially decreases HIV risk when taken consistently—this study explores an alternative delivery method.
Dr. Steve Taylor, who serves as a principal investigator for the Purpose 5 trial and leads the Clinical Service at Birmingham Heartlands HIV service, expressed, “These injectable PrEP solutions hold the potential to revolutionize HIV prevention both in the UK and globally.”
He noted that the Purpose 1 Trial in Africa yielded a remarkable outcome, with none of the 2,134 women receiving Lenacapivir testing positive for HIV.
Dr. Taylor stated further, “This trial seeks to assess whether these injections offer additional advantages as an HIV prevention approach and if they are a desirable option for women.”
Women are being specifically targeted for participation since they tend to be less likely to take daily PrEP tablets to mitigate their HIV risk.
Data from government sources indicate that in 2023, 75% of men who have sex with men, identified by NHS sexual health…
—-
Author : [email protected]
Publish date : 2025-04-18 16:22:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8